B+
Bull case
25%
Probability
Target price
$19.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
KZIA
Kazia TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$12.00
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-04-28 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-04-28
Recent news sentiment (30D)
+0.2
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+70.3
Score
AI commentary
Recent disclosed newsflow is directionally positive but mostly company-controlled: January's preliminary TNBC response update, March's catalyst map and runway framing, and April's SETDB1 platform expansion. The packet contains no recent trusted-news coverage and no usable social-coverage readout, so sentiment should be treated as event-driven and low-conviction rather than broadly validated by third-party follow-through.
RankAlpha Sentiment Codex - 2026-04-28
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30eventFDA path-forward update for paxalisib in glioblastomaHigh impact
Kazia's March 2026 investor fact sheet lists a Q2 2026 update from FDA discussions on paxalisib's commercial and development path forward in GBM; for a low-coverage biotech, any clarity on registrational strategy or trial design could materially reset expectations, but the event is still guidance-level until disclosed [#IR-2026-03-27].
2026-09-30event2H 2026 neuro-oncology readouts in GBM and brain metastasesHigh impact
Kazia flagged 2H 2026 readouts from neuro-oncology-focused clinical trials in patients with GBM and brain metastases, which are the most decision-relevant proof points for paxalisib beyond narrative platform expansion [#IR-2026-03-27].
2026-09-30catalystPipeline expansion beyond paxalisib may broaden strategic optionalityHigh impact
Kazia added a first-in-class SETDB1-targeted platform in April 2026 and separately guided to Q2 2026 advancement of NDL2 toward IND-enabling studies; these programs can improve partnering narrative, but they are earlier-stage than paxalisib and should not yet be treated as near-term value anchors [#PR-2026-04-13] [#IR-2026-03-27].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-28 • Updated nightlySource: Internal modelMethodology